http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1656365-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6042509de7544921c96de43b9da1438
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14
filingDate 2004-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2009-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43924a037ee9d8ac4ae44ad9b223b279
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2dd6af04d6ea3c688060b2abb860397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a280977be74d3fee92bfec840ef513b
publicationDate 2009-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1656365-B1
titleOfInvention A method for the preparation of enantiomerically pure mirtazapine
abstract The invention provides a method for the preparation of enantiomerically pure mirtazapine, said method comprising a step of ring closure of a compound of formula (II) wherein X is a leaving group, said step comprising treatment with an acid, whereby mirlazapine with enantiomeric excess is formed by the ring closure of the compound of formula (II) with enantiomeric excess by treatment with a suitable acid in the absence of a solvent or a suitable combination of an acid and an organic solvent.
priorityDate 2003-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66992899
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID51691407
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227547523
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159156
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12362975
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86498
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226421655
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128988724
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227547528
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6954
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53442681
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10221435
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399027
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399028
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248498456
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11580055
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399029
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129825398
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4205
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467960550
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227546993
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227547068
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66992898
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227547070

Total number of triples: 43.